GlassScriptPhysician profile
Lilian Serpas
NPI 1396375390
$9,869.79
in general payments reported to CMS, 2019-2025
22 companies · $4,516 in 2025
The $4,516 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $1,654 · 2024: $3,486 · 2025: $4,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,214 · Education: $432 · Travel and Lodging: $10.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,214.30 |
| Education | $431.92 |
| Travel and Lodging | $10.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,336.60 | 2022-2025 | |
| Dermavant Sciences, INC. | $1,355.48 | 2023-2024 | Vtama |
| Ucb, INC. | $1,186.26 | 2024-2025 | Bimzelx |
| Incyte Corporation | $837.01 | 2023-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $808.25 | 2023-2025 | |
| Genzyme Corporation | $422.85 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $417.51 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $397.94 | 2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $264.20 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $252.01 | 2023-2024 | Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $243.33 | 2023-2025 | Dupixent |
| Organon LLC | $237.57 | 2025 | Vtama |
| Janssen Biotech, INC. | $192.01 | 2023-2025 | Tremfya |
| Botanix Sb INC | $173.85 | 2025 | Sofdra |
| Leo Pharma INC. | $167.22 | 2025 | Anzupgo, Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $129.84 | 2024-2025 | Ycanth |
| Lilly USA, LLC | $123.02 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Pharmaceuticals, INC. | $120.17 | 2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Amgen INC. | $55.64 | 2022 | |
| Genentech USA, INC. | $25.18 | 2023 | Erivedge |
| Lnhc, INC | $23.86 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilian Serpas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.